Scientific summary of the 3rd International Symposium on Propionibacteria and Bifidobacteria: Dairy and Probiotic Applications by González de los Reyes-Gavilán, Clara
1 
 
Scientific Summary of the 3rd International Symposium on Propionibacteria and 1 
Bifidobacteria: Dairy and Probiotic applications 2 
 3 
The Propiobifido2010 Symposium dealt with the current advances in dairy and 4 
probiotic applications of Bifidobacterium and Propionibacterium genera. Both Gram-5 
positive bacteria are grouped within the Actinobacteria phylum and share some 6 
common physiological properties. Research into propionibacteria has been 7 
classically oriented to their technological properties in dairy products, particularly 8 
Swiss-type cheeses, whilst research on bifidobacteria has mainly been focused on 9 
their probiotic potential. Nowadays both, the probiotic potential and the improvement 10 
of technological characteristics of propionibacteria and bifidobacteria, are scientific 11 
areas of increasing interest. Communications presented in this Symposium focused 12 
on five major subjects which are commented on below.   13 
 14 
1. Physiology and Metabolism 15 
The physiology and metabolism of propionibacteria and bifidobacteria determine 16 
their relationship with the external environment and are the basis of their probiotic 17 
properties. They are important determinants of the interaction of propionibacteria and 18 
bifidobacteria with other microorganisms from the intestinal environment. In this 19 
Symposium it was highlighted that the enhancement of butyrate and gas production 20 
after consumption of these bacteria, or in the presence of oligofructose, could be 21 
attributed to mechanisms of cross-feeding between bifidobacteria and butyrate-22 
producing intestinal bacteria. Proteins, sugars and other structures from the bacterial 23 
cell-envelope participate in the cross-talk with the host or in the interaction with the 24 
external environment, then influencing health-promoting or technological properties 25 
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of bifidobacteria and propionibacteria. In the Symposium studies on exocellular 26 
polysaccharides, lipoteichoic acids, and ABC-type multidrug efflux systems 27 
conferring antibiotic resistance in bifidobacteria, as well as bacteriocins and lipolytic 28 
esterases from Propionibacterium freudenreichi were presented. In addition to the 29 
interactions with other intestinal microorganisms and the host, the bacteria present in 30 
the intestine will also interact with components of the diet. It was reported in this 31 
Symposium that some Bifidobacterium strains can convert in vitro inactive glycosides 32 
of anthocyanins and isoflavones into their corresponding aglycones, probably 33 
through the beta-glucosidase microbial activity; aglycones can then undergo 34 
chemical or enzymatic degradation towards more biologically active forms. Also 35 
reported was the phytase activity of several bifidobacteria strains able to convert anti-36 
nutrient phytic acid, the most abundant form of phosphate storage in vegetables, into 37 
myo-inositol triphosphate, some of whose isomers could display health-promoting 38 
activities. It has also been stated  that milk proteins  conjugated to galactose formed 39 
via Maillard reaction, as well as lactulose-derived galactooligosaccharides obtained 40 
by enzymatic transglycosilation of lactulose, could act as prebiotic substrates.  41 
So far a very challenging issue has been to determine the physiological status of 42 
microbes. Traditionally the only distinction that was made was between cultured / 43 
alive and un-cultured / dead cells; however, now we know that other statuses do 44 
exist. Fluorescent probes allow a more reliable determination of the viability and 45 
physiological status of microbial cells than traditional plate counts. Two works were 46 
presented on the use of such probes to determine the viability of Propionibacterium 47 
and some lactic acid bacteria. 48 
 49 
2. Industrial and Technological Applications 50 
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The commercial use of these two microbial groups constitutes the main driving 51 
force in this area of knowledge. Some communications addressed the selection and 52 
characterization of probiotic properties of bifidobacteria and propionibacteria strains 53 
isolated from classical foods (raw milk, Emmental cheese, fermented products….) as 54 
well as from new, living being environments. This last case is of the isolation and 55 
characterization of propionibacteria strains from the stomach of human adults, these 56 
microorganisms displaying high resistance to gastrointestinal stressing factors, or 57 
those isolated from the intestine of laying hens for their application in poultry. A 58 
significant number of communications dealt with the characterization of bifidobacteria 59 
population in infant faeces and on the isolation and characterization of bifidobacteria 60 
from human milk for the application of these strains in infant formulas. Studies on 61 
probiotic and technological properties were also undertaken in classical and newly 62 
designed fermented products containing propionibacteria and bifidobacteria. In this 63 
way, it is interesting to remark that miniaturized models of dairy products were 64 
optimized and presented in this Symposium for monitoring technological properties 65 
and for predicting probiotic behaviour of propionibacteria.  66 
Bifidobacteria are generally more sensitive than propionibacteria and lactobacilli 67 
to environmental factors. Their viability and stability in foods can be improved by 68 
tailoring the production conditions, by utilization of protectants and new technologies 69 
(i.e. by microencapsulation), or by adaptation to stressing conditions. In general, 70 
stress-tolerant mutants became more resistant to technological harsh conditions than 71 
their parental strains, thus contributing to their better survival in both food matrices 72 
and gastrointestinal tract. In addition, adapted strains represent an alternative 73 
strategy to study genetic variants of a strain under stressful conditions when no other 74 
genetic tools are easily available. Thus, works on heat-shock and aerobic tolerant 75 
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derivative Bifidobacterium strains were presented in this Symposium and were 76 
characterized by genomic and proteomic approaches.  77 
 78 
3. Health Effects: Clinical and in vivo Data 79 
The use of probiotics in medicine is steadily increasing as demonstrated by more 80 
than 600 records currently contained in the Cochrane Central Register of Controlled 81 
Trials testing the efficacy of probiotics for different health applications. Specifically, in 82 
the frame of the applications of probiotics in gastroenterology, three human 83 
intervention studies were presented in this Symposium. One of them using yoghurt 84 
supplemented with a Bifidobacterium longum strain for alleviation of constipation in 85 
children and adolescents in Brazil. The other two works analyzed intestinal 86 
microbiota dynamics of adults fed yoghurt containing commercial bifidobacteria and 87 
lactobacilli strains, in Canada and Spain. In the last case, adults were previously 88 
submitted to antibiotic treatment. Remarkably, some new and very promising 89 
applications tested in animals by the administration of bifidobacteria were presented 90 
in this Symposium. They include the amelioration of endotoxemia in diabetes type II 91 
and metabolic syndrome and the regulation of the composition of host fat tissue by 92 
host-microbe-diet interactions.   93 
It is evident that more human intervention studies are needed in order to 94 
accomplish requirements from the European Food Safety Authority (EFSA) for the 95 
approval of health claims in probiotic-containing products in Europe. To help in this 96 
task, and before accomplishing time-consuming and expensive in vivo and human 97 
intervention studies, a previous screening of the probiotic potential of candidate 98 
strains would be useful and very convenient. Relating to this, in this Symposium an in 99 
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vitro cellular model was presented to test the efficacy of putative probiotic strains 100 
against gut dysfunctions related to Irritable Bowel Syndrome (IBS).  101 
 102 
4. Health Effects: Mechanisms 103 
The mechanisms of health promotion by probiotics can include modulation of 104 
intestinal microbiota, improvement of the gut barrier, competitive exclusion or 105 
displacement of pathogens, and immune modulation. A body of work was presented 106 
in this Symposium on the immune-stimulatory effect of Bifidobacterium and 107 
Propionibacterium strains and of some specific sub-cellular components of these 108 
microorganisms such as surface polysaccharides or proteins. In vitro studies have 109 
been directed to test the effect on different cell-components of the human immune 110 
system: maturation patterns of dendritic cells and T-helper lymphocytes, stimulation 111 
of natural killer cells, B- and T-lymphocytes, and cytokine production patterns by 112 
natural killer, dendritic and peripheral blood mononuclear cells. Aggregation capacity 113 
and adhesion to intestinal epithelial cell lines has been underlined as important in 114 
vitro characteristics that could be related with the ability to modulate the immune 115 
system by intestinal bacteria. In this regard, some communications presented in this 116 
Symposium investigated adhesion to human intestinal cell lines and the aggregating 117 
capability of several Bifidobacterium strains in an attempt to correlate these 118 
properties with their immunomodulating potential. Some P. freudenreichii and 119 
Bifidobacterium strains (B. longum and Bifidobacterium bifidum) have shown 120 
promising immunomodulatory capability and good perspectives for the alleviation of 121 
Inflammatory Bowel Disease (IBD) symptoms when tested using in vivo models of 122 
colitis in mice. A study was also presented assessing the efficiency of a B. longum 123 
strain against rotavirus infections in a mouse model.  124 
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5. “Omics” and Molecular Approaches 126 
Sequencing and functional analysis of genomes from P. freudenreichii and 127 
several Bifidobacterium species presented in this Symposium are significantly 128 
contributing to improving our understanding of the adaptation capability of these 129 
microorganisms to different environments. In the case of bifidobacteria, different 130 
species can differ in their adaptation strategies for the use of the diverse components 131 
of diet, also displaying different ways of interaction with other members of the 132 
intestinal microbiota. On the other hand, the application of genetic tools, such as 133 
microarray technology, knock-out insertional mutation and others, is contributing to 134 
the rapid advance of our knowledge of some metabolic pathways and functionality of 135 
several proteins of interest. A huge effort has been made in this area in the species 136 
B. breve; the characterization of a two component regulatory system, a serpin, and 137 
some mechanisms of bile stress response and the metabolism of some sugars are 138 
under investigation and some results were presented in the Symposium. The 139 
availability of genome sequences is facilitating the development of typing techniques, 140 
such as multilocus sequence typing, of strains in species of Propionibacterium and 141 
Bifidobacterium.  142 
 143 
It is expected that within a short period of time significant advances in our 144 
understanding of the functionality and behaviour of some microorganisms of these 145 
two bacterial genera will occur. The large increase of immunomodulatory studies 146 
presented in Propiobifido2010, with regard to the previous Symposia, highlights the 147 
interest of the Scientific Community to unravel the mechanisms that direct the cross-148 
talk between proionibacteria and bifidobacteria and the human host. It is also 149 
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expected that the new beneficial actions that are being demonstrated in animal 150 
models, as well as the requirements of the new European Regulation on Health 151 
Claims in food products, will force an increase in the number of human intervention 152 
studies. Propiobifido2010 provided the opportunity to present and discuss the latest 153 
scientific advances for people interested in propionibacteria and bifidobacteria. For 154 
sure, the forthcoming Propiobifido2013 Symposium will deliver exciting news in this 155 
research field.  156 
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